Please assess the completion status of the following clinical trial:

Trial Title: Israeli 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria include:~* Clinical diagnosis of advanced heterogeneous emphysema~* Age \> 18 years at the time of initial presentation~* Clinically significant dyspnea (MRC Dyspnea \>/= 2)~* Failure of standard medical therapy to provide relief of symptoms~* BUN, creatinine, ALT, AST, alkaline phosphatase, WBC, hematocrit, platelet count, PT and PTT within normal limits~* Pulmonary function tests~Exclusion Criteria:~* Alpha-1 protease inhibitor deficiency verified by a serum level of \< 80 mg% or knowledge of PI\*ZZ genotype~* Body mass index \< 15 kg/m2 or \> 35 kg/m2~* Clinically significant asthma (reversible airway obstruction), chronic bronchitis or bronchiectasis~* Tobacco use within 16 weeks of the initial clinic visit~* Allergy to fish or pork products or sensitivity to tetracycline~* FEV1 \<20% with DLCO \<20% or homogeneous disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- single (Type: EXPERIMENTAL): BLVR treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).